News / Taiwan / economic_daily
Applied BioCode Shares Jump Over 5% on Strong September Revenue Growth
Health Technology · Biotechnology · economic_daily · 2026-10-08
6598
Applied BioCode (ABC) saw its shares climb over 5% after reporting a 73.65% year-over-year revenue increase in September, driven by rising demand for respiratory testing in North America.
What Happened
Revenue Performance: Applied BioCode (ABC) reported a strong September revenue of 77.22 million TWD, marking a 73.65% year-over-year increase. The company's cumulative revenue for the first nine months of the year also surged by 70.58%, fueled by successful market expansion and increased customer demand for its diagnostic solutions.
Market Drivers: The company is benefiting from a trend of consolidation among large North American laboratories, which has boosted demand for its high-throughput, automated diagnostic platforms. Analysts expect the combination of new client acquisitions and seasonal demand during the flu season to provide significant momentum for Q4 operations.
Core Technology: Leveraging its proprietary "Digital BioBarcode" platform, Applied BioCode has established a strong presence in the U.S. in-vitro diagnostics market. The company collaborates with IDEXX in animal health and has secured FDA clearance for several human molecular diagnostic kits and the BioCode MDx-3000 automated system.
Future Outlook: Applied BioCode is currently developing an advanced "20+1" respiratory molecular diagnostic panel that integrates COVID-19 testing. The company plans to seek FDA approval for this new iteration, which is expected to expand its diagnostic coverage and help clients further streamline their laboratory workflows.